In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be ...

CMS said April 4 it will not move forward with a Biden-era proposal to allow Medicare coverage of GLP-1 drugs when prescribed ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

From the weight-loss boom to must-have sweet treats, we discover the top 10 trends dominating food and beverage in 2025.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

It was hoped that the drug would offer improved weight loss for patients with diabetes, who typically have a tougher time ...

Americans by the millions are flocking to new medicines that can combat obesity, and WSJ editor Bradley Olson is one of them. He lost 40 pounds after taking a five-month course of a GLP-1 ...

Move over, chips and cookies – snacking is getting a GLP-1-era makeover. A recent Cornell University and Numerator study found households with at least one user of GLP-1 – medications like ...